SLIDE 1
Clinical Metabolomics: Analytical Tool for Drug Development.
Vladimir Tolstikov 1,*
1 Director of Metabolomics, BERG LLC, Framingham, MA 01701, U.S.A.
Clinical Metabolomics: Analytical Tool for Drug Development. Vladimir - - PowerPoint PPT Presentation
Clinical Metabolomics: Analytical Tool for Drug Development. Vladimir - - PowerPoint PPT Presentation
Clinical Metabolomics: Analytical Tool for Drug Development. Vladimir Tolstikov 1, * 1 Director of Metabolomics, BERG LLC, Framingham, MA 01701, U.S.A. * Corresponding author: vladimir.tolstikov@berghealth.com 1 Clinical Metabolomics: Analytical
SLIDE 2
SLIDE 3
Abstract: It is recognized that altered metabolic states reports on the chronic and acute disease statuses. Decades of research have shown that metabolism is not a self- regulating network operating independently but rather heavily integrated into every cellular process and involved in organ system functions. Therefore global monitoring of metabolic processes is recommended for more comprehensive understanding of the initiation and advancement of disease. Mass spectrometry based metabolomics, in particular, demonstrates tremendous promise in delivering high throughput quantitative information on alterations in metabolism associated with disease onset/progression and response to pharmaceutical intervention. Recent advances in mass spectrometry and informatics tools have facilitated emerging in house OMICS platforms capable of translating biological output into viable therapeutic candidates and assist in stratifying patient populations. At BERG, we have implemented an industrial level high throughput metabolomics platform providing both high quality and depth of information allowing for reliable and broadest capture of the metabolome for the pre-clinical and clinical matrixes analyzed. Global metabolomics platform dedicated for theranostic and clinical studies as well as tracer metabolomics are harvested to facilitate CDx biomarkers discovery in a unique way. Highlights of the BERG’s in-depth patient stratification approaches as well as biology based drugs are presented. Keywords: Metabolomics, discovery, clinical, network, patient stratification, CDx markers.
3
SLIDE 4
4
SLIDE 5
5
Gut ut Mi Micr crob
- biome
iome
SLIDE 6
6
SLIDE 7
7
SLIDE 8
8
6 Nsamples Pvariables
Szymanska E., Saccenti E., Smilde A. and Westerhuis J. (2012). Metabolomics, 8:3-16
….. It is becoming increasingly evident that many biological studies are underpowered with regard to their ability to come to a robust and statistically significant and justifiable biological conclusion .….
SLIDE 9
9
SLIDE 10
10 10
SLIDE 11
11 11
SLIDE 12
12 12
SLIDE 13
13 13
SLIDE 14
14 14 14
Robert Powers: The Current State of Drug Discovery and a Potential Role for NMR Metabolomics, J. Med. Chem., 2014, 57 (14), pp 5860–5870
SLIDE 15
15 15
SLIDE 16
16 16
SLIDE 17
17 17
SLIDE 18
18 18 18
SLIDE 19
19 19 19
SLIDE 20
20 20 20
SLIDE 21
21 21 21
SLIDE 22
22 22 22
Case summary
- 1. A ketogenic diet dramatically increases and sustains endogenous FGF21 production in wild-type and PPARα KO
mice indicating PPARα-independent regulation of FGF21.
- 2. A cluster of metabolites associated with FGF21 production in PPARα KO mice was identified and suggests this
increase is associated with increased metabolic stress in the liver.
- 3. Pattern correlation and two way ANOVA analyses suggest significant changes to the transmethylation pathway
and glutathione metabolism in response to acute dietary challenges.
SLIDE 23
23 23 23
SLIDE 24
24 24 24
SLIDE 25
25 25 25
SLIDE 26
26 26 26
SLIDE 27
27 27 27
SLIDE 28
28 28 28
SLIDE 29
29 29 29
SLIDE 30
30 30 30
SLIDE 31
31 31 31
SLIDE 32
32 32 32
SLIDE 33
33 33 33
SLIDE 34
34 34 34
SLIDE 35
35
SLIDE 36